These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 1501395)

  • 21. The role of imaging in the surveillance of urologic malignancies.
    Bradford TJ; Montie JE; Hafez KS
    Urol Clin North Am; 2006 Aug; 33(3):377-96. PubMed ID: 16829272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Interferon therapy in urology].
    Kriegmair M; Hofstetter A
    Urologe A; 1989 Mar; 28(2):116-21. PubMed ID: 2470188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of immunotherapy in urologic malignancies.
    Abubakr YA; Redman BG
    Cancer Treat Res; 1996; 88():235-48. PubMed ID: 9239484
    [No Abstract]   [Full Text] [Related]  

  • 24. [Immunotherapy and urological malignancy].
    Marumo K
    Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):361-71. PubMed ID: 1712869
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclic interferon gamma application in patients with renal cell carcinoma.
    Grups JW; Frohmüller HG
    Prog Clin Biol Res; 1990; 350():257-62. PubMed ID: 2117285
    [No Abstract]   [Full Text] [Related]  

  • 26. [Study on adoptive immunotherapy in patients with renal cell carcinoma. II. Plasmapheresis with adoptive immunotherapy using LAK cells and IL-2].
    Usui A
    Nihon Hinyokika Gakkai Zasshi; 1990 Jul; 81(7):1058-64. PubMed ID: 2214469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of disseminated renal cell cancer with combinations of interleukin-2, lymphokine-activated killer cells, and alpha-interferon.
    Stoter G; Goey SH; Batchelor D; Eggermont AM; Lamers C; Gratama JW; Bolhuis RL
    Prog Clin Biol Res; 1992; 378():225-33. PubMed ID: 1301583
    [No Abstract]   [Full Text] [Related]  

  • 28. Biomarker classification, validation, and what to look for in 2017 and beyond.
    Davis JW
    BJU Int; 2017 May; 119(5):812-814. PubMed ID: 28117555
    [No Abstract]   [Full Text] [Related]  

  • 29. A literature analysis of prognostic factors for response and quality of response of patients with renal cell carcinoma to interleukin-2-based therapy.
    Elias L; Hunt WC
    Oncology; 2001; 61(2):91-101. PubMed ID: 11528247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Urologic oncology].
    Meran JG; Schramek P
    Wien Med Wochenschr; 2011 Aug; 161(15-16):365. PubMed ID: 21953424
    [No Abstract]   [Full Text] [Related]  

  • 31. [Treatment waiting time in urological oncology].
    Rouprêt M
    Prog Urol; 2008 Jul; 18(7):426-7. PubMed ID: 18602601
    [No Abstract]   [Full Text] [Related]  

  • 32. High-dose interleukin-2 in the therapy of metastatic renal-cell carcinoma.
    Parkinson DR; Sznol M
    Semin Oncol; 1995 Feb; 22(1):61-6. PubMed ID: 7855620
    [No Abstract]   [Full Text] [Related]  

  • 33. Interferon-alpha and interleukin-2 in the treatment of renal cell cancer.
    Holdener EE; Emmons RP; Brunda M; Evans L; Levitt D
    Prog Clin Biol Res; 1990; 348():61-9. PubMed ID: 2201034
    [No Abstract]   [Full Text] [Related]  

  • 34. Adoptive immunotherapy of urologic tumors.
    Belldegrun A; Rosenberg SA
    Cancer Treat Res; 1989; 46():213-33. PubMed ID: 2577191
    [No Abstract]   [Full Text] [Related]  

  • 35. [Cell therapy for renal cell carcinoma].
    Kawai K
    Gan To Kagaku Ryoho; 2002 Oct; 29(10):1745-51. PubMed ID: 12402424
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferons in renal-cell carcinoma: status and prospects.
    De Mulder PH; Debruyne FM; Beniers AJ
    Prog Clin Biol Res; 1990; 348():49-59. PubMed ID: 1696737
    [No Abstract]   [Full Text] [Related]  

  • 37. The management of urological malignancies during pregnancy.
    Loughlin KR
    Br J Urol; 1995 Nov; 76(5):639-44. PubMed ID: 8535688
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recombinant alpha-interferon plus vinblastine in metastatic renal-cell cancer: analysis of response and survival in 58 evaluable patients.
    Bergerat JP; Ford J; Herbrecht R; Dufour P; Oberling F; Jacqmin D; Bollack C; Prevot G; Salze P; Jurascheck F
    Prog Clin Biol Res; 1990; 348():137-50. PubMed ID: 2385604
    [No Abstract]   [Full Text] [Related]  

  • 39. [Biochemical modulation of chemotherapy of urologic malignancies].
    Okada K
    Hinyokika Kiyo; 1993 Dec; 39(12):1195-6. PubMed ID: 8285170
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genitourinary cancer.
    Hudes GR; Grana G; Deshields MS; Ozols RF
    Cancer Chemother Biol Response Modif; 1992; 13():508-40. PubMed ID: 1389919
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.